ArticlemBio2018
Virulence Role of the GlcNAc Side Chain of the Lancefield Cell Wall Carbohydrate Antigen in Non-M1-Serotype Group A
Article in mBio, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 59 citations in OpenAlex.
- Rational selection of antigenic targets for Group A Streptococcus vaccine: updates, challenges and opportunities.NPJ vaccines · 2026Review
- A conserved glycan motif induces broadly reactive functional antibodies against the zoonotic pathogenScience advances · 2026Article
- The "Cairo Accord"- towards the eradication of RHD: revisited (2026).Frontiers in cardiovascular medicine · 2026Review
- Natural variation of the streptococcal group A carbohydrate biosynthesis genes impacts host-pathogen interaction.Microbial genomics · 2025Article
- Recombinant production platform for Group A Streptococcus glycoconjugate vaccines.NPJ vaccines · 2025Article
- The burden of group AiScience · 2025Review
- The intricate pathogenicity of Group AVirulence · 2024Review
- Review
- Review
- Identification of distinct impacts of CovS inactivation on the transcriptome of acapsular group A streptococci.mSystems · 2023Article
- Progress towards a glycoconjugate vaccine against Group A Streptococcus.NPJ vaccines · 2023Review
- Synthetic Glycans to Improve Current Glycoconjugate Vaccines and Fight Antimicrobial Resistance.Chemical reviews · 2022Review
- Acute Rheumatic Fever and Rheumatic Heart Disease: Highlighting the Role of Group A Streptococcus in the Global Burden of Cardiovascular Disease.Pathogens (Basel, Switzerland) · 2022Review
- Glycan-mediated molecular interactions in bacterial pathogenesis.Trends in microbiology · 2022Review
- IgG2 rules: N-acetyl-β-D-glucosamine-specific IgG2 and Th17/Th1 cooperation may promote the pathogenesis of acute rheumatic heart disease and be a biomarker of the autoimmune sequelae ofFrontiers in cardiovascular medicine · 2022Article
- Immunobiology of the Classical Lancefield Group A Streptococcal Carbohydrate Antigen.Infection and immunity · 2021Article
- FBXO2/SCF ubiquitin ligase complex directs xenophagy through recognizing bacterial surface glycan.EMBO reports · 2021Article
- Pathogenomics of Streptococcus ilei sp. nov., a newly identified pathogen ubiquitous in human microbiome.Journal of microbiology (Seoul, Korea) · 2021Article
- The role of vaccines in combatting antimicrobial resistance.Nature reviews. Microbiology · 2021Review
- A brief review on Group A Streptococcus pathogenesis and vaccine development.Royal Society open science · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
Classification of streptococci is based upon expression of unique cell wall carbohydrate antigens. All serotypes of group A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.